European Journal of Clinical Pharmacology

SJR Rank #5,913H-index: 128SJR: 0.886Best quartile: Q2APC: US$3,090
Journal website: aims, scope and author guidelines
Publisher

Springer Science and Business Media Deutschland GmbH

Country

Germany

Type

journal

SJR by Edition

2022202500.250.50.751

Subject Categories

  • Medicine (miscellaneous)Q2
  • PharmacologyQ2
  • Pharmacology (medical)Q2

Areas: Medicine · Pharmacology, Toxicology and Pharmaceutics

Most published research topics

Pharmacogenetics and Drug MetabolismAntibiotics Pharmacokinetics and EfficacyAnalytical Methods in PharmaceuticalsPharmaceutical studies and practicesPharmaceutical Practices and Patient OutcomesPharmacological Effects and Toxicity StudiesBlood Pressure and Hypertension StudiesDrug Transport and Resistance MechanismsPharmacovigilance and Adverse Drug ReactionsEpilepsy research and treatment

Source: OpenAlex

Publication Statistics

2025 Docs3-Year DocsCitable Docs0150300450600

Documents per Year

20222025055110165220

Detailed Information

ISSN

0031-6970, 1432-1041

SJR Best Quartile

Q2

Region

Western Europe

Citations per Document (2 years)

3.48

References per Document

41.75

Coverage

1968-2026

Scope

The European Journal of Clinical Pharmacology publishes original papers on all aspects of clinical pharmacology and drug therapy in humans. Manuscripts are welcomed on the following topics: therapeutic trials, pharmacokinetics/pharmacodynamics, pharmacogenetics, drug metabolism, adverse drug reactions, drug interactions, all aspects of drug development, development relating to teaching in clinical pharmacology, pharmacoepidemiology, and matters relating to the rational prescribing and safe use of drugs. Methodological contributions relevant to these topics are also welcomed. Data from animal experiments are accepted only in the context of original data in man reported in the same paper. EJCP will only consider manuscripts describing the frequency of allelic variants in different populations if this information is linked to functional data or new interesting variants. Highly relevant differences in frequency with a major impact in drug therapy for the respective population may be submitted as a letter to the editor. Straightforward phase I pharmacokinetic or pharmacodynamic studies as parts of new drug development will only be considered for publication if the paper involves -a compound that is interesting and new in some basic or fundamental way, or -methods that are original in some basic sense, or -a highly unexpected outcome, or -conclusions that are scientifically novel in some basic or fundamental sense.

Metrics from SCImago Journal Rank 2025. View on SCImago